JLE

Hématologie

MENU

Traitement par alisertib des lymphomes T périphériques en rechute ou réfractaires : des résultats décevants Volume 25, numéro 3, Mai-Juin 2019

  • [1] Mak V., Hamm J., Chhanabhai M. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare longterm survivors. J Clin Oncol. 2013;31:1970-1976.
  • [2] O’Connor O.A., Pro B., Pinter-Brown L. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182-1189.
  • [3] Coiffier B., Pro B., Prince H.M. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.
  • [4] Friedberg J.W., Mahadevan D., Cebula E. Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014;32:44-50.
  • [5] O’Connor O.A., Özcan M., Jacobsen E.D. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019;37:613-623. 8